fda compounding glp-1 enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Why the FDA Issued 30

These effects can improve glucose tolerance, which is especially meaningful in Type 2 Diabetes and Metabolic Syndrome

5, 6 Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1, 7, 8 leading to investigations into its potential for the treatment of obesity

Characteristic symptoms include sudden-onset pain in the right upper quadrant or epigastrium, pain radiating to the right shoulder, episodes lasting 30 minutes to several hours (often after fatty meals), and associated nausea and vomiting

In fact, fat-free mass lost accounts for 25-40% of the total pounds lost, while age-related declines in fat-free mass are only 8% per decade